The coronavirus illness 2019 (COVID-19) international pandemic brought on by extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to position an immense burden on societies and well being care programs. A key element of COVID-19 management efforts is serological take a look ating to find out the group prevalence of SARS-CoV-2 publicity and quantify particular person immune responses to prior SARS-CoV-2 an infection or vaccination. Right here, we describe a laboratory-developed antibody take a look at that makes use of available research-grade reagents to detect SARS-CoV-2 publicity in affected person blood samples with excessive sensitivity and specificity.
We additional present that this delicate take a look at affords the estimation of viral spike-specific IgG titers from a single pattern measurement, thereby offering a easy and scalable technique to measure the energy of a person’s immune response. The accuracy, adaptability, and cost-effectiveness of this take a look at make it a wonderful possibility for scientific deployment within the ongoing COVID-19 pandemic. A course of analysis will assess implementation utilizing an tailored Normalisation Measure Growth (NoMAD) questionnaire and qualitative interviews. An financial feasibility evaluation will inform a future financial analysis.
Serological surveillance has turn into an vital public well being device throughout the COVID-19 pandemic. Detection of protecting antibodies and seroconversion after SARS-CoV-2 an infection or vaccination can assist information affected person care plans and public well being insurance policies. Serology assessments can detect antibodies towards previous infections; consequently, they can assist overcome the shortcomings of molecular assessments, which may detect solely energetic infections. That is vital, particularly when contemplating that many COVID-19 sufferers are asymptomatic.
On this examine, we describe an enzyme-linked immunosorbent assay (ELISA)-based qualitative and quantitative serology take a look at developed to measure IgG and IgA antibodies towards the SARS-CoV-2 spike glycoprotein. The take a look at could be deployed utilizing generally accessible laboratory reagents and tools and shows excessive specificity and sensitivity. Moreover, we show that IgG titers in affected person samples could be estimated from a single measurement, enabling the assay’s use in high-throughput scientific environments.
Protocol for a feasibility examine incorporating a randomised pilot trial with an embedded course of analysis and feasibility financial evaluation of ThinkCancer!: a main care intervention to expedite most cancers analysis in Wales
In comparison with the remainder of Europe, the UK has comparatively poor most cancers outcomes, with late analysis and a gradual referral course of being main contributors. Basic practitioners (GPs) are sometimes confronted with sufferers presenting with a large number of non-specific signs that could possibly be most cancers. Security netting can be utilized to handle diagnostic uncertainty by guaranteeing sufferers with obscure signs are appropriately monitored, which is now much more essential as a result of ongoing COVID-19 pandemic and its main influence on most cancers referrals.
The ThinkCancer! workshop is an academic behaviour change intervention aimed on the entire normal observe crew, designed to enhance main care approaches to make sure well timed analysis of most cancers. The workshop will encompass educating and consciousness periods, the appointment of a Security Netting Champion and the event of a bespoke Security Netting Plan and has been tailored so it may be delivered remotely. This examine goals to evaluate the feasibility of the ThinkCancer! intervention for a future definitive randomised managed trial.
The ThinkCancer! examine is a randomised, multisite feasibility trial, with an embedded course of analysis and feasibility financial evaluation. Twenty-three to 30 normal practices can be recruited throughout Wales, randomised in a ratio of two:1 of intervention versus management who will comply with traditional care. The workshop can be delivered by a GP educator and can be tailored iteratively all through the trial interval. Baseline observe traits can be collected through questionnaire. We can even accumulate main care intervals (PCI), 2-week wait (2WW) referral charges, conversion charges and detection charges at baseline and 6 months post-randomisation. Participant suggestions, researcher reflections and financial costings can be collected following every workshop.
SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 Could 2020
The outbreak of coronavirus illness 2019 (COVID-19) was first reported in Wuhan, China, in December 2019. To research the prevalence of COVID-19 in Wuhan, we performed serologic assessments on 35,326 people from 4 totally different communities to estimate cumulative incidence of an infection. Our outcomes confirmed that 1,332 people (3.77%) confirmed optimistic COVID-19 antibody (both IgM or IgG). Males had a decrease positivity fee than females (3.02% versus 4.52%). The antibody positivity charges confirmed a transparent pattern of improve in line with sufferers’ ages and different amongst totally different communities.
Coronavirus illness 2019 (COVID-19) was first detected in December 2019 in Wuhan, China. Afterwards, various public well being interventions had been applied, together with lock-down, face masks ordinances, and social distancing. Research that depend on viral RNA testing of symptomatic sufferers have proven that these multifaceted interventions contributed to the management of the COVID-19 outbreak in Wuhan and delayed the epidemic’s development. Nevertheless, these estimates of confirmed instances might miss giant numbers of asymptomatic sufferers and recovered symptomatic sufferers who weren’t examined.
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 201.6 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 440.4 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 459.6 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 500.4 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 627.6 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 519.6 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 376.8 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 501.6 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 412.8 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 537.6 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 589.2 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 750 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 337.2 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 592.8 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 513.6 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 414 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 206.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 206.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 530.4 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 159.6 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 559.2 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 176.4 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 538.8 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 538.8 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 166.8 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 313.2 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 316.8 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 338.4 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 178.8 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 186 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV Core 24 Antigen |
|||
| 00151-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core 24 antigen. |
|||
HCV Core 24 Antigen |
|||
| 00151-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core 24 antigen. |
|||
HCV core recombinant antigen |
|||
| 00152-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV core recombinant antigen |
|||
| 00152-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
HCV NS5 2061-2302aa recombinant antigen |
|||
| 00157-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
|||
HCV NS5 2061-2302aa recombinant antigen |
|||
| 00157-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
|||
HCV NS5 2212-2313aa recombinant antigen |
|||
| 00158-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
|||
HCV NS5 2212-2313aa recombinant antigen |
|||
| 00158-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
|||
HAV VP1-P2A recombinant antigen |
|||
| 00159-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HAV VP1-P2A recombinant antigen a.a. 722-830. |
|||
HAV VP1-P2A recombinant antigen |
|||
| 00159-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HAV VP1-P2A recombinant antigen a.a. 722-830. |
|||
HAV VP4-VP2 recombinant antigen |
|||
| 00160-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HAV VP4-VP2 recombinant antigen a.a. 55-164. |
|||
HAV VP4-VP2 recombinant antigen |
|||
| 00160-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HAV VP4-VP2 recombinant antigen a.a. 55-164. |
|||
HAV P2C-P3A recombinant antigen |
|||
| 00161-V-01mg | Virogen | 0,1 mg | EUR 321 |
|
Description: HAV P2C-P3A recombinant antigen a.a. 1492-1606. |
|||
HAV P2C-P3A recombinant antigen |
|||
| 00161-V-1000ug | Virogen | 1000 ug | EUR 1539 |
|
Description: HAV P2C-P3A recombinant antigen a.a. 1492-1606. |
|||
To research the prevalence of COVID-19 in Wuhan, we performed serologic assessments on 35,326 people to estimate the cumulative incidence of an infection. The outcomes counsel that public well being interventions might play vital roles within the management of COVID-19. A beforehand match and properly 72-year-old man was referred to the acute medical unit with acute shortness of breath and confusion. He had offered 6 months earlier to his Basic Practitioner with a 6-month historical past of weight reduction and lethargy.
